Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial Comparing Cabazitaxel Combination Hormone Therapy to Hormone Therapy Alone in Metastatic Prostate Cancer or High Risk Disease

NCT01978873 is registered in ClinicalTrials.gov with Örebro University, Sweden as lead sponsor.

NCT NCT01978873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01978873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial Comparing Cabazitaxel Combination Hormone Therapy to Hormone Therapy Alone in Metastatic Prostate Cancer or High Risk Disease
Lead sponsor
Örebro University, Sweden
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2012
Completion date
November 30, 2019
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer